This study evaluates adherence to the latest Society for Vascular Surgery (SVS) guidelines on imaging surveillance, physician evaluation, and surgical intervention for abdominal aortic aneurysm (AAA). AI-based natural language processing applied retrospectively identified AAA patients from imaging scans at a tertiary care center between January-March 2019 and 2021, excluding the pandemic period. Retrospective chart review assessed demographics, comorbidities, imaging, and follow-up adherence. Statistical significance was set at p<0.05. Among 479 identified patients, 279 remained in the final cohort following exclusion of deceased patients. Imaging surveillance adherence was 67.7% (189/279), with males comprising 72.5% (137/189) (Figure 1). The mean age for adherent patients was 73.9 (SD ±9.5) vs. 75.2 (SD ±10.8) for non-adherent patients (Table 1). Adherent females were significantly younger than non-adherent females (76.7 vs. 81.1 years; p=0.003) with no significant age difference in adherent males. Adherent patients were more likely to be evaluated by a vascular provider within six months (p<0.001), but aneurysm size did not affect imaging adherence: 3.0-4.0cm (p=0.24), 4.0-5.0cm (p=0.88), >5.0cm (p=0.29). Based on SVS surgical criteria, 18 males (AAA >5.5cm) and 17 females (AAA >5.0cm) qualified for intervention and repair rates increased in 2021. 34 males (20 in 2019 v. 14 in 2021) and 7 females (2021 only) received surgical intervention below the threshold for repair. Despite consistent SVS guidelines, adherence remains moderate. AI-based detection and follow-up algorithms may enhance adherence and long-term AAA patient outcomes, however further research is needed to assess the specific impacts of AI.

To perform a systematic review on artificial intelligence (AI) studies focused on identifying and differentiating pelvic gynecological tumors on ultrasound scans. Studies developing or validating AI models for diagnosing gynecological pelvic tumors on ultrasound scans were eligible for inclusion. We systematically searched PubMed, Embase, Web of Science, and Cochrane Central from their database inception until April 30th, 2024. To assess the quality of the included studies, we adapted the QUADAS-2 risk of bias tool to address the unique challenges of AI in medical imaging. Using multi-level random effects models, we performed a meta-analysis to generate summary estimates of the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. To provide a reference point of current diagnostic support tools for ultrasound examiners, we descriptively compared the pooled performance to that of the well-recognized ADNEX model on external validation. Subgroup analyses were performed to explore sources of heterogeneity. From 9151 records retrieved, 44 studies were eligible: 40 on ovarian, three on endometrial, and one on myometrial pathology. Overall, 95% were at high risk of bias - primarily due to inappropriate study inclusion criteria, the absence of a patient-level split of training and testing image sets, and no calibration assessment. For ovarian tumors, the summary AUC for AI models distinguishing benign from malignant tumors was 0.89 (95% CI: 0.85-0.92). In lower-risk studies (at least three low-risk domains), the summary AUC dropped to 0.87 (0.83-0.90), with deep learning models outperforming radiomics-based machine learning approaches in this subset. Only five studies included an external validation, and six evaluated calibration performance. In a recent systematic review of external validation studies, the ADNEX model had a pooled AUC of 0.93 (0.91-0.94) in studies at low risk of bias. Studies on endometrial and myometrial pathologies were reported individually. Although AI models show promising discriminative performances for diagnosing gynecological tumors on ultrasound, most studies have methodological shortcomings that result in a high risk of bias. In addition, the ADNEX model appears to outperform most AI approaches for ovarian tumors. Future research should emphasize robust study designs - ideally large, multicenter, and prospective cohorts that mirror real-world populations - along with external validation, proper calibration, and standardized reporting. This study was pre-registered with Open Science Framework (OSF): https://doi.org/10.17605/osf.io/bhkst.

Online adaptive magnetic resonance-guided radiotherapy (MRgRT) has emerged as a state-of-the-art treatment option for multiple tumour entities, accounting for daily anatomical and tumour volume changes, thus allowing sparing of relevant organs at risk (OARs). However, the annotation of treatment-relevant anatomical structures in context of online plan adaptation remains challenging, often relying on commercial segmentation solutions due to limited availability of clinically validated alternatives. The aim of this study was to investigate whether an open-source artificial intelligence (AI) segmentation network can compete with the annotation accuracy of a commercial solution, both trained on the identical dataset, questioning the need for commercial models in clinical practice. For 47 pelvic patients, T2w MR imaging data acquired on a 1.5 T MR-Linac were manually contoured, identifying prostate, seminal vesicles, rectum, anal canal, bladder, penile bulb, and bony structures. These training data were used for the generation of an in-house AI segmentation model, a nnU-Net with residual encoder architecture featuring a streamlined single image inference pipeline, and re-training of a commercial solution. For quantitative evaluation, 20 MR images were contoured by a radiation oncologist, considered as ground truth contours (GTC) and compared with the in-house/commercial AI-based contours (iAIC/cAIC) using Dice Similarity Coefficient (DSC), 95% Hausdorff distances (HD95), and surface DSC (sDSC). For qualitative evaluation, four radiation oncologists assessed the usability of OAR/target iAIC within an online adaptive workflow using a four-point Likert scale: (1) acceptable without modification, (2) requiring minor adjustments, (3) requiring major adjustments, and (4) not usable. Patient-individual annotations were generated in a median [range] time of 23 [16-34] s for iAIC and 152 [121-198] s for cAIC, respectively. OARs showed a maximum median DSC of 0.97/0.97 (iAIC/cAIC) for bladder and minimum median DSC of 0.78/0.79 (iAIC/cAIC) for anal canal/penile bulb. Maximal respectively minimal median HD95 were detected for rectum with 17.3/20.6 mm (iAIC/cAIC) and for bladder with 5.6/6.0 mm (iAIC/cAIC). Overall, the average median DSC/HD95 values were 0.87/11.8mm (iAIC) and 0.83/10.2mm (cAIC) for OAR/targets and 0.90/11.9mm (iAIC) and 0.91/16.5mm (cAIC) for bony structures. For a tolerance of 3 mm, the highest and lowest sDSC were determined for bladder (iAIC:1.00, cAIC:0.99) and prostate in iAIC (0.89) and anal canal in cAIC (0.80), respectively. Qualitatively, 84.8% of analysed contours were considered as clinically acceptable for iAIC, while 12.9% required minor and 2.3% major adjustments or were classed as unusable. Contour-specific analysis showed that iAIC achieved the highest mean scores with 1.00 for the anal canal and the lowest with 1.61 for the prostate. This study demonstrates that open-source segmentation framework can achieve comparable annotation accuracy to commercial solutions for pelvic anatomy in online adaptive MRgRT. The adapted framework not only maintained high segmentation performance, with 84.8% of contours accepted by physicians or requiring only minor corrections (12.9%) but also enhanced clinical workflow efficiency of online adaptive MRgRT through reduced inference times. These findings establish open-source frameworks as viable alternatives to commercial systems in supervised clinical workflows.

Accurate estimation of treatment response can help clinicians identify patients who would potentially benefit from systemic therapy. This study aimed to develop and externally validate a model for predicting treatment response to systemic therapy in advanced gallbladder cancer (GBC). We recruited 399 eligible GBC patients across four institutions. Multivariable logistic regression analysis was performed to identify independent clinical factors related to therapeutic efficacy. This deep learning (DL) radiomics signature was developed for predicting treatment response using multiphase enhanced CT images. Then, the DL radiomic-clinical (DLRSC) model was built by combining the DL signature and significant clinical factors, and its predictive performance was evaluated using area under the curve (AUC). Gradient-weighted class activation mapping analysis was performed to help clinicians better understand the predictive results. Furthermore, patients were stratified into low- and high-score groups by the DLRSC model. The progression-free survival (PFS) and overall survival (OS) between the two different groups were compared. Multivariable analysis revealed that tumor size was a significant predictor of efficacy. The DLRSC model showed great predictive performance, with AUCs of 0.86 (95% CI, 0.82-0.89) and 0.84 (95% CI, 0.80-0.87) in the internal and external test datasets, respectively. This model showed great discrimination, calibration, and clinical utility. Moreover, Kaplan-Meier survival analysis revealed that low-score group patients who were insensitive to systemic therapy predicted by the DLRSC model had worse PFS and OS. The DLRSC model allows for predicting treatment response in advanced GBC patients receiving systemic therapy. The survival benefit provided by the DLRSC model was also assessed. Question No effective tools exist for identifying patients who would potentially benefit from systemic therapy in clinical practice. Findings Our combined model allows for predicting treatment response to systemic therapy in advanced gallbladder cancer. Clinical relevance With the help of this model, clinicians could inform patients of the risk of potential ineffective treatment. Such a strategy can reduce unnecessary adverse events and effectively help reallocate societal healthcare resources.

In abdominal interventional procedures, achieving precise registration of 2D ultrasound (US) frames with 3D computed tomography (CT) scans presents a significant challenge. Traditional tracking methods often rely on high-precision sensors, which can be prohibitively expensive. Furthermore, the clinical need for real-time registration with a broad capture range frequently exceeds the performance of standard image-based optimization techniques. Current automatic registration methods that utilize deep learning are either heavily reliant on manual annotations for training or struggle to effectively bridge the gap between different imaging domains. To address these challenges, we propose a novel diffusion-stimulated CT-US registration model. This model harnesses the physical diffusion properties of US to generate synthetic US images from preoperative CT data. Additionally, we introduce a synthetic-to-real domain adaptation strategy using a diffusion model to mitigate the discrepancies between real and synthetic US images. A dual-stream self-supervised regression neural network, trained on these synthetic images, is then used to estimate the pose within the CT space. The effectiveness of our proposed approach is verified through validation using US and CT scans from a dual-modality human abdominal phantom. The results of our experiments confirm that our method can accurately initialize the US image pose within an acceptable range of error and subsequently refine it to achieve precise alignment. This enables real-time, tracker-independent, and robust rigid registration of CT and US images.

Thyroid cancer is the most prevalent malignant tumour in the endocrine system, with its incidence steadily rising in recent years. Current central processing units (CPUs) and graphics processing units (GPUs) face significant challenges in terms of processing speed, energy consumption, cost, and scalability in the identification of thyroid nodules, making them inadequate for the demands of future green, efficient, and accessible healthcare. To overcome these limitations, this study proposes an efficient quantized inference method using a field-programmable gate array (FPGA). We employ the YOLOv4-tiny neural network model, enhancing software performance with the K-means + + optimization algorithm and improving hardware performance through techniques such as 8-bit weight quantization, batch normalization, and convolutional layer fusion. The study is based on the ZYNQ7020 FPGA platform. Experimental results demonstrate an average accuracy of 81.44% on the Tn3k dataset and 81.20% on the internal test set from a Chinese tertiary hospital. The power consumption of the FPGA platform, CPU (Intel Core i5-10200 H), and GPU (NVIDIA RTX 4090) were 3.119 watts, 45 watts, and 68 watts, respectively, with energy efficiency ratios of 5.45, 0.31, and 5.56. This indicates that the FPGA's energy efficiency is 17.6 times that of the CPU and 0.98 times that of the GPU. These results show that the FPGA not only significantly outperforms the CPU in speed but also consumes far less power than the GPU. Moreover, using mid-to-low-end FPGAs yields performance comparable to that of commercial-grade GPUs. This technology presents a novel solution for medical imaging diagnostics, with the potential to significantly enhance the speed, accuracy, and environmental sustainability of ultrasound image analysis, thereby supporting the future development of medical care.

Artificial intelligence (AI) has been proposed to assist radiologists in reporting multiparametric magnetic resonance imaging (mpMRI) of the prostate. We evaluate the diagnostic performance of radiologists with different levels of experience when reporting mpMRI with the support of available AI-based software (Quantib Prostate). This is a single-center study (NCT06298305) involving 110 patients. Those with a positive mpMRI (PI-RADS ≥ 3) underwent targeted plus systematic biopsy (TBx plus SBx), while those with a negative mpMRI but a high clinical suspicion of prostate cancer (PCa) underwent SBx. Three readers with different levels of experience, identified as R1, R2, and R3 reviewed all mpMRI. Inter-reader agreement among the three readers with or without the assistance of Quantib Prostate as well as sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy for the detection of clinically significant PCa (csPCa) were assessed. 102 patients underwent prostate biopsy and the csPCa detection rate was 47%. Using Quantib Prostate resulted in an increased number of lesions identified for R3 (101 vs. 127). Inter-reader agreement slightly increased when using Quantib Prostate from 0.37 to 0.41 without vs. with Quantib Prostate, respectively. PPV, NPV and diagnostic accuracy (measured by the area under the curve [AUC]) of R3 improved (0.51 vs. 0.55, 0.65 vs.0.82 and 0.56 vs. 0.62, respectively). Conversely, no changes were observed for R1 and R2. Using Quantib Prostate did not enhance the detection rate of csPCa for readers with some experience in prostate imaging. However, for an inexperienced reader, this AI-based software is demonstrated to improve the performance. Name of registry: clinicaltrials.gov. NCT06298305. Date of registration: 2022-09.

The early prediction of lymph node positivity (LN+) after neoadjuvant chemotherapy (NAC) is crucial for optimizing individualized treatment strategies. This study aimed to integrate radiomic features and clinical biomarkers through machine learning (ML) approaches to enhance prediction accuracy by focusing on patients with locally advanced gastric cancer (LAGC). We retrospectively enrolled 277 patients with LAGC and randomly divided them into training (n = 193) and validation (n = 84) sets at a 7:3 ratio. In total, 1,130 radiomics features were extracted from pre-treatment portal venous phase computed tomography scans. These features were linearly combined to develop a radiomics score (rad score) through feature engineering. Then, using the rad score and clinical biomarkers as input features, we applied simple statistical strategies (relying on a single ML model) and integrated statistical strategies (including classification model integration techniques, such as hard voting, soft voting, and stacking) to predict LN+ post-NAC. The diagnostic performance of the model was assessed using receiver operating characteristic curves with corresponding areas under the curve (AUC). Of all ML models, the stacking classifier, an integrated statistical strategy, exhibited the best performance, achieving an AUC of 0.859 for predicting LN+ in patients with LAGC. This predictive model was transformed into a publicly available online risk calculator. We developed a stacking classifier that integrates radiomics and clinical biomarkers to predict LN+ in patients with LAGC undergoing surgical resection, providing personalized treatment insights.

We propose a multimodal spatiotemporal graph neural network (STG) framework to predict colorectal cancer liver metastasis (CRLM) progression. Current clinical models do not effectively integrate the tumor's spatial heterogeneity, dynamic evolution, and complex multimodal data relationships, limiting their predictive accuracy. Our STG framework combines preoperative CT imaging and clinical data into a heterogeneous graph structure, enabling joint modeling of tumor distribution and temporal evolution through spatial topology and cross-modal edges. The framework uses GraphSAGE to aggregate spatiotemporal neighborhood information and leverages supervised and contrastive learning strategies to enhance the model's ability to capture temporal features and improve robustness. A lightweight version of the model reduces parameter count by 78.55%, maintaining near-state-of-the-art performance. The model jointly optimizes recurrence risk regression and survival analysis tasks, with contrastive loss improving feature representational discriminability and cross-modal consistency. Experimental results on the MSKCC CRLM dataset show a time-adjacent accuracy of 85% and a mean absolute error of 1.1005, significantly outperforming existing methods. The innovative heterogeneous graph construction and spatiotemporal decoupling mechanism effectively uncover the associations between dynamic tumor microenvironment changes and prognosis, providing reliable quantitative support for personalized treatment decisions.

Accurate classification of focal liver lesions is crucial for diagnosis and treatment in hepatology. However, traditional supervised deep learning models depend on large-scale annotated datasets, which are often limited in medical imaging. Recently, Vision-Language models (VLMs) such as Contrastive Language-Image Pre-training model (CLIP) has been applied to image classifications. Compared to the conventional convolutional neural network (CNN), which classifiers image based on visual information only, VLM leverages multimodal learning with text and images, allowing it to learn effectively even with a limited amount of labeled data. Inspired by CLIP, we pro-pose a Liver-VLM, a model specifically designed for focal liver lesions (FLLs) classification. First, Liver-VLM incorporates class information into the text encoder without introducing additional inference overhead. Second, by calculating the pairwise cosine similarities between image and text embeddings and optimizing the model with a cross-entropy loss, Liver-VLM ef-fectively aligns image features with class-level text features. Experimental results on MPCT-FLLs dataset demonstrate that the Liver-VLM model out-performs both the standard CLIP and MedCLIP models in terms of accuracy and Area Under the Curve (AUC). Further analysis shows that using a lightweight ResNet18 backbone enhances classification performance, particularly under data-constrained conditions.